VCU Massey is the first U.S. site in a global phase 2a trial for PTX-100, targeting cutaneous T-cell lymphoma. The BIPAVE-001 trial is evaluating AI-081, a PD-1 and VEGF bispecific antibody, for ...
While cancers such as breast, lung, and prostate frequently dominate public health discussions, there is a far less recognised but equally aggressive form - sarcoma. It affects thousands across the UK ...
Moleculin Biotech, Inc. announced promising results from their Phase 1B/2 trial of Annamycin for treating soft tissue sarcoma lung metastases, showing a robust clinical benefit rate of 59.4% among ...
A recently published study from Fred Hutch Cancer Center dramatically expands the number of FDA-approved cancer drugs ...
Every July, Sarcoma Awareness Month reminds us of a cancer that’s often sidelined in public discourse. However, sarcoma is not just one disease, it is a group of rare cancers with over 150 subtypes, ...
Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the ...
A new paper published today in the Canadian Medical Association Journal offers fresh modelling that shows cancer cases and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results